BCG is derived from a weakened strain of the bacterium Mycobacterium bovis, originally developed as a vaccine against tuberculosis and administered extensively to children worldwide. In bladder cancer therapy, however, BCG is introduced into the bladder at much higher concentrations. Traditionally, its mechanism was thought to rely on direct infection of cancer cells, which would then attract and activate immune cells to target the tumor. This paradigm suggested a localized immune activation. Yet, until now, the full spectrum of immune responses triggered by BCG, especially the systemic facets, remained inadequately explored.

Dr. Michael Glickman, a physician-scientist and acting director of the Marie-Josée Kravis Center for Cancer Immunobiology at MSK, emphasized how BCG stands as a classic example of a treatment validated by clinical outcomes long before its molecular and cellular underpinnings were understood. His team’s recent publication in Cancer Cell reveals that beyond its local bladder effects, BCG reprograms hematopoietic stem and progenitor cells (HSPCs) within the bone marrow. This reprogramming bolsters the generation of myeloid cells—a crucial subset of innate immune cells—thereby amplifying the body’s broader immune competence against tumors.

This expansion of the innate immune response is particularly significant because the innate immune system serves as the body’s first responder, offering rapid and generalized defense mechanisms. Unlike the adaptive immune system—which relies on prior exposure and develops highly specific responses—innate immunity can provide an immediate antitumor effect. The study demonstrates that BCG’s immunotherapeutic benefit partly arises from its ability to enhance this innate arm of immunity, essentially “training” bone marrow progenitors to yield immune cells better equipped to detect and destroy cancer cells.

The investigative team combined meticulous analyses of blood samples from bladder cancer patients undergoing BCG therapy with advanced studies using mouse models of bladder cancer. Leveraging a sophisticated technique known as Progenitor Input Enrichment single-cell sequencing (PIE-seq), developed at Weill Cornell Medicine, the researchers could deeply profile rare circulating HSPCs from patients’ blood draws. This innovative approach bypassed the need for more invasive bone marrow biopsies and provided unprecedented insights into cellular reprogramming following BCG treatment.

Findings revealed significant shifts in gene expression within these progenitor cells, indicating that BCG therapy redefines the developmental trajectory of immune cells in the bone marrow. The newly programmed myeloid cells emerging from these progenitors displayed enhanced tumor-fighting capacities, supporting the concept that BCG acts systemically, far beyond the bladder, to orchestrate a refined innate immune response.

Complementing their patient data, mouse model studies established that BCG bacteria administered intravesically could translocate from the bladder to the bone marrow, where live bacteria could be cultured. This observation decisively confirmed that BCG acts not just as a local stimulus but also as a systemic immunomodulator. Consistent with prior observations of BCG vaccination reducing susceptibility to viral infections, the researchers postulate that BCG’s capacity to prime bone marrow progenitors underlies broad immune benefits extending beyond cancer therapy.

The research also explored therapeutic synergies between BCG and checkpoint inhibitors, another class of immunotherapy that functions by lifting inhibitory signals on T cells, thus reigniting their ability to recognize and attack tumors. Mouse experiments demonstrated that combining BCG with checkpoint inhibitors resulted in superior tumor shrinkage and prolonged survival compared to either therapy alone. This synergy arises because BCG-stimulated myeloid cells enhance T cell activation, effectively creating a mutually reinforcing immune environment for cancer eradication.

Dr. Steven Josefowicz, associate professor of pathology and laboratory medicine at Weill Cornell Medicine and co-senior author on the study, noted that these findings have profound implications for the future of cancer immunotherapy. They suggest that strategically targeting the bone marrow to reprogram innate immunity can substantially augment the efficacy of existing treatments. This strategy might open avenues for improving immunotherapies across various cancer types, fostering immune resilience at the fundamental cellular level.

Despite the promising nature of these discoveries, several questions remain. Future research will need to address how best to harness and optimize this bone marrow reprogramming therapeutically and whether intravesical administration of BCG can potentiate immunotherapy responses in cancers beyond the bladder. As Dr. Glickman remarks, while these concepts are compelling, translating them into clinical practice requires careful, rigorous investigation.

This study was made possible by the extensive collaboration between clinical scientists and researchers, supported by ongoing collection of patient samples through MSK urologic surgeon Dr. Eugene Pietzak, as well as contributions from McGill University. The multidisciplinary nature of this research exemplifies the integration of clinical insights with cutting-edge molecular techniques necessary to unlock the complexities of cancer immunotherapy.

In conclusion, this research reinvigorates our understanding of BCG as not just a bladder-specific treatment but as a potent systemic immune trainer. By revealing the pivotal role of the bone marrow in mediating BCG’s effects, it opens new horizons for designing therapies that not only attack tumors directly but also harness the body’s intrinsic defense architectures for sustained and enhanced cancer control.

Subject of Research: Cancer immunotherapy; BCG therapy; innate immunity; hematopoietic stem and progenitor cells; bone marrow reprogramming; bladder cancer

Article Title: BCG Immunotherapy Reprograms Bone Marrow Progenitors to Enhance Innate Immunity Against Cancer

News Publication Date: 29-May-2025

Web References:

• https://www.mskcc.org/cancer-care/types/bladder/treatment/bacillus-calmette-guerin-therapy
• http://dx.doi.org/10.1016/j.ccell.2025.05.002
• https://www.sciencedirect.com/science/article/pii/S0092867423007961?via%3Dihub

References: The publication in Cancer Cell, May 29, 2025

Keywords: Immunology; Cancer immunotherapy; Medical treatments; Innate immune system; BCG therapy; Hematopoietic stem cells; Bone marrow; Bladder cancer; Checkpoint inhibitors

Hepatitis B remains a pressing concern, infecting approximately 250 million individuals worldwide and causing over one million deaths annually. The World Health Organization considers it the second most deadly infectious disease after HIV. Chronic HBV infection leads to long-term liver damage, a situation that significantly elevates the risk of cancer and liver cirrhosis. Thus, the need for more effective treatments and a deeper understanding of the virus’s life cycle is paramount.

The research team focused on the role of a viral protein called X, which is crucial for establishing HBV infection. This protein has long puzzled scientists due to its dual function—it promotes viral replication while simultaneously driving the oncogenic processes that can lead to cancer. The central question of how a virus encodes its own essential proteins while simultaneously undergoing episodes of replication prompted this innovative investigation.

To examine these processes, the researchers ingeniously employed atomic force microscopy to visualize the intricate interactions between HBV DNA and human histones—proteins that package and protect DNA within the nucleus of eukaryotic cells. By successfully creating a hepatitis B minichromosome, they were able to study the initial interactions between the viral genome and the host’s cellular machinery. This work contributed significantly to understanding how HBV subverts the pathways of gene expression and employs cellular components to facilitate its own infection.

The findings revealed that, contrary to conventional wisdom, the packaging of the viral genome occurs in such a way that it is essential for the transcription process leading to X protein production. The assembly into nucleosomes—a structural unit composed of DNA wrapped around histone proteins—built a functional context in which transcription factors could effectively interact with DNA. This transformation of viral DNA into a more organized structure is crucial for the activation of the viral transcription machinery, which ultimately leads to HBV replication.

In seeking to identify potential therapeutic candidates, the researchers investigated five known small-molecule compounds that disrupt chromatin formation. Among these, CBL137—a compound currently undergoing clinical trials as an anticancer treatment—demonstrated the most promise by effectively blocking the production of the X protein in liver cells even at low doses. This result opens the door for further trials to verify its efficacy and safety as a potential anti-HBV therapeutic agent.

The biochemical processes behind viral gene expression have long represented a challenging frontier in virology. Understanding the interplay between a virus and the host’s chromatin landscape sheds light on how infections can persist and avoid clearance by the immune system. This study highlights the relevance of the nucleosome architecture in viral oncogenes and the intricate strategies viruses use to hijack cellular resources for their propagation.

The collaboration between the three prestigious institutions fostered a multidisciplinary approach that combined expertise in virology, chemical biology, and genetics. Leveraging state-of-the-art technologies available across these institutions allowed the researchers to effectively probe the fundamental biology of HBV. Such collaborative frameworks not only accelerate the pace of discovery but also enhance the reliability of experimental findings, presenting a model that can be applied to other infectious diseases.

The researchers also detailed the implications of their findings for global public health, emphasizing that current treatment methodologies are insufficient. Existing antiviral therapies can suppress HBV replication but often fail to eliminate the infection entirely. The potential of CBL137 represents a new strategy aimed at disrupting the layered defense that HBV has developed, affording hope of achieving a functional cure.

As the study progresses towards preclinical trials in animal models, it carries the potential not only to pave the pathway for effective treatment options against HBV, but also to explore potential applications for other pathogens known to exploit similar chromatin dynamics, such as herpesviruses and papillomaviruses. The understanding achieved by investigating the foundational aspects of the HBV lifecycle could lead to broader insights applicable in tackling various viral diseases.

Overall, the collaboration among MSK, Weill Cornell Medicine, and The Rockefeller University exemplifies the profound impacts that interdisciplinary efforts can yield in scientific research. The engaging dialogue among researchers hailing from different fields spurs innovation and accelerates the translation of basic scientific discoveries into practical medical advancements. With a commitment to illuminating the complexities of viral infections and a deftly orchestrated strategy to tackle HBV, the research community is poised to contribute meaningfully to combating this global health crisis.

As the study concludes its promising preliminary phase and moves into further validation stages, the scientific community, and particularly those tasked with combating viral diseases, will eagerly await the forthcoming developments from this vital research endeavor.

This exploration into the life cycle of HBV not only supports the imperative need for advanced therapeutic interventions, but also reinforces the continual importance of fundamental research. Observations from this study may catalyze significant breakthroughs and inspire future research trajectories aimed at controlling viral infections and associated diseases, encapsulating the essence of scientific inquiry—where rigorous questioning and experimentation are aligned towards comprehensive health solutions.

Subject of Research: Hepatitis B Virus Molecular Mechanisms
Article Title: A Nucleosome Switch Primes Hepatitis B Virus Infection
News Publication Date: February 20, 2025
Web References: Cell
References: Published study in Cell
Image Credits: Memorial Sloan Kettering Cancer Center

Keywords: Hepatitis B, Viral Infection, Nucleosomes, Cancer Research, Chromatin Biology, Antiviral Therapy, Molecular Mechanisms, Interdisciplinary Collaboration.